ePrivacy and GPDR Cookie Consent by TermsFeed Generator

NEULASTA

6MG INJ SOL 1X0,6ML III

Maximum ex-factory price/Ex-factory price ? 17344,19 CZK
Legal basis of maximum ex-factory price/ex-factory price ? Maximum ex-factory price announced under the law.

Informace o základní úhradě

Preliminarily effective core reimbursement from health insurance ? 4238,07 CZK
Preliminarily effective maximum reimbursement from health insurance ? 5488,34 CZK
Legal basis of reimbursement from health insurance ? Reimbursement set by the law. Rozhodnutí dosud nenabylo právní moci, je však předběžně vykonatelné.
Indication restriction of reimbursement ? Pegfilgrastim je hrazen v indikaci zkrácení doby trvání neutropenie a snížení incidence febrilní neutropenie u pacientů léčených cytotoxickou chemoterapií pro maligní nádorové onemocnění (s výjimkou chronické myeloidní leukémie).
Prescribing doctor's specialisation ? Clinical oncology, pediatric hematology and oncology, radiation onkology and gynecologic oncology
Hematology and transfusion medicine, pediatric oncology a hematology
Reporting limit ? E: Unless it is advisable to transfer the prescription of the product to another doctor under paragraph 2 in light of the effect and safety of the product, the "E" symbol will mark the product in the decision.
Rough price for the final consumer ? 20403,98 CZK
Rough payment for the final consumer (for 1 prescribed package dispensed) ? 14915.64 CZK
Eligible extra payment ?
Eligible extra payment for individuals aged 65 and older ?
Medicinal products reimbursed from health insurance contain the amount of the maximum manufacturer´s price or the producer´s notified price for products which are not subjected to the regulation of the maximum manufacturer´s price, the amount of reimbursement from health insurance and the estimated price for the end consumer (pharmacy price).

Back to list